I review the key issues that arise in financing health care delivery. I begin by documenting
the key features of health care markets that make financing so central in this sector, such as …

We review the literature on financial intermediation in the process by which new medical
therapeutics are financed, developed, and delivered. We discuss the contributing factors that …

Biomedical research is intended to benefit human beings and their health. Toward that end,
scientific norms involve examining and criticizing the work of others and prioritizing …

This study delves into the intricate relationship between government subsidies and
corporate environmental, social, and governance (ESG) performance in the context of …

How does a firm's market power in existing products affect its incentives to innovate? We
explore this fundamental question using granular project-level and firm-level data from the …

We examine the effect of increased healthcare costs on local economic conditions. We use
private equity (PE) buyouts of US hospital systems as a shock to the healthcare costs faced …

We examine real outcomes for biotech startups going public around the Jumpstart Our
Business Startups (JOBS) Act. Reduced compliance costs associate with greater innovation …

Purpose Biotech companies stand as key actors in pharmaceutical innovation. The high risk
and long timelines inherent with their R&D investments might hinder their access to funding …

We develop a theory of optimal financing for R&D-intensive firms that uses their unique
features—large capital outlays, long gestation periods, high upside, and low probabilities of …

Conflict of interest's guidelines and regulations have been focused on ensuring good
science, mainly understood as a science free from external coercion. However, recent major …